Health
Arbutus Biopharma swings to $169.7M net income in Q1 2026
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.
United StatesHealth
Health
BrainsWay net income doubles as Deep TMS shipments hit all-time high
BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.
Health
Dyne advances muscular dystrophy pipeline; BLA submission set for Q2
Dyne Therapeutics (NASDAQ:DYN) ended the first quarter of 2026 with $972.2 million in cash, cash equivalents, and marketable securities.
Health
Warby Parker beats Q1 targets as high-margin eye exams drive customer spend
Warby Parker (NYSE:WRBY) reported first-quarter results for 2026 that exceeded internal guidance across all key financial metrics, signaling resilient demand for its affordable luxury eyewear and integrated vision services.
Health
IDEXX raises outlook as high pet healthcare demand drives revenue surge
IDEXX Laboratories (NASDAQ:IDXX) increased its financial projections for 2026 following a first quarter marked by robust demand for pet healthcare services and significant margin expansion within its core diagnostic segments.
Health
BrightSpring Health profits soar as revenue hits $3.6B in record first quarter
BrightSpring Health Services (NASDAQ:BTSG) reported a landmark first quarter for 2026, delivering substantial growth across all key financial metrics.
Health
Kodiak Sciences to present strong KSI-101 results at major vision conferences
Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.
Health
Pentair shares rise as efficiency drives 10% jump in adjusted earnings
Pentair (NYSE:PNR) reported a strong start to the 2026 fiscal year, characterized by steady sales growth and a significant expansion in operating efficiency.
Health
FDA grants priority review for Johnson & Johnson’s Nipocalimab in wAIHA
Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).
Health
UnitedHealth Group raises 2026 outlook following solid Q1 growth
UnitedHealth Group (NYSE:UNH) today reported financial results for the first quarter of 2026, delivering growth across its primary business platforms and raising its full-year earnings outlook.
Health
Hims & Hers shares surge as FDA schedules landmark peptide review
Hims & Hers Health (NYSE:HIMS) shares surged this week, closing 13.7% higher after the U.S. Food and Drug Administration (FDA) announced a high-stakes meeting to re-evaluate the regulatory status of several popular peptides.
Health
Arbutus Biopharma receives FDA fast track designation for HBV candidate imdusiran
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company specializing in chronic infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV).